X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (20) 20
index medicus (16) 16
male (14) 14
female (13) 13
middle aged (13) 13
aged (12) 12
cirrhosis (10) 10
gastroenterology & hepatology (9) 9
adult (7) 7
patients (6) 6
therapy (6) 6
drug therapy, combination (5) 5
haart (5) 5
hepatitis c, chronic - complications (5) 5
hepatitis c, chronic - drug therapy (5) 5
hepatocellular carcinoma (5) 5
liver (5) 5
management (5) 5
risk factors (5) 5
treatment outcome (5) 5
aged, 80 and over (4) 4
analysis (4) 4
antiviral agents (4) 4
antiviral agents - therapeutic use (4) 4
antiviral therapy (4) 4
care and treatment (4) 4
genotype (4) 4
hepatitis c virus (4) 4
liver cirrhosis - complications (4) 4
medicine, research & experimental (4) 4
survival (4) 4
anti-hiv agents - pharmacology (3) 3
antiretroviral therapy, highly active (3) 3
antiviral agents - adverse effects (3) 3
biological response modifiers (3) 3
carcinoma, hepatocellular - therapy (3) 3
clinical trials (3) 3
diagnosis (3) 3
gastroenterology and hepatology (3) 3
genotypes (3) 3
hepacivirus - genetics (3) 3
hepatitis (3) 3
hepatitis b (3) 3
hepatitis c (3) 3
hiv (3) 3
hiv infection (3) 3
hiv infections - drug therapy (3) 3
hiv-1 (3) 3
incidence (3) 3
infection (3) 3
infectious diseases (3) 3
interferon (3) 3
kaplan-meier estimate (3) 3
liver cancer (3) 3
liver cirrhosis (3) 3
liver neoplasms - therapy (3) 3
natural-history (3) 3
neoplasm staging (3) 3
prospective studies (3) 3
ribavirin (3) 3
ribavirin - therapeutic use (3) 3
severity of illness index (3) 3
time factors (3) 3
abridged index medicus (2) 2
antineoplastic agents - therapeutic use (2) 2
cancer (2) 2
carbamates - adverse effects (2) 2
carbamates - therapeutic use (2) 2
carcinoma, hepatocellular - mortality (2) 2
carcinoma, hepatocellular - pathology (2) 2
cd4 lymphocyte count (2) 2
cell cycle - drug effects (2) 2
cell differentiation (2) 2
cell line, tumor (2) 2
comorbidity (2) 2
direct-acting antivirals (2) 2
disease progression (2) 2
drug therapy (2) 2
drugs (2) 2
era (2) 2
failure (2) 2
general practice / family medicine (2) 2
guidelines (2) 2
hepacivirus - drug effects (2) 2
hepatitis c, chronic (2) 2
hepatitis c, chronic - virology (2) 2
hepatitis-c virus (2) 2
hepatology (2) 2
hepatoma (2) 2
hiv infections - complications (2) 2
hiv infections - virology (2) 2
hiv protease inhibitors - pharmacology (2) 2
hiv-infected patients (2) 2
impact (2) 2
internal medicine (2) 2
italy (2) 2
lipodystrophy (2) 2
liver cirrhosis - etiology (2) 2
liver neoplasms - mortality (2) 2
liver neoplasms - pathology (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


世界肝病学杂志:英文版(电子版), ISSN 1948-5182, 2016, Volume 8, Issue 22, pp. 949 - 956
AIM: To check the safety and efficacy of boceprevir/telaprevir with peginterferon/ribavirin for hepatitis C virus(HCV) genotype 1 in the real-world settings.... 
Boceprevir;Telaprevir;Chronic | therapy;Peg-interferon;Ribavirin | hepatitis;Antiviral | Antiviral therapy | Boceprevir | Telaprevir | Chronic hepatitis | Peg-interferon | Ribavirin | Observational Study
Journal Article
by Bertoli, Ada and Sorbo, Maria Chiara and Aragri, Marianna and Lenci, Ilaria and Teti, Elisabetta and Polilli, Ennio and Di Maio, Velia Chiara and Gianserra, Laura and Biliotti, Elisa and Masetti, Chiara and Magni, Carlo F and Babudieri, Sergio and Nicolini, Laura A and Milana, Martina and Cacciatore, Pierluigi and Sarmati, Loredana and Pellicelli, Adriano and Paolucci, Stefania and Craxì, Antonio and Morisco, Filomena and Palitti, Valeria Pace and Siciliano, Massimo and Coppola, Nicola and Iapadre, Nerio and Puoti, Massimo and Rizzardini, Giuliano and Taliani, Gloria and Pasquazzi, Caterina and Andreoni, Massimo and Parruti, Giustino and Angelico, Mario and Perno, Carlo Federico and Cento, Valeria and Ceccherini-Silberstein, Francesca and Andreone, Pietro and Baldanti, Fausto and Barbarini, Giorgio and Boccaccio, Vincenzo and Boglione, Lucio and Bolis, Matteo and Bonora, Stefano and Borghi, Vanni and Brancaccio, Giuseppina and Bruno, Savino and Bruzzone, Bianca and Calvaruso, Vincenza and Caporaso, Nicola and Ciaccio, Antonio and Ciancio, Alessia and Colombatto, Piero and Cozzolongo, Raffaele and D'Ambrosio, Cecilia and D'Ettorre, Gabriella and De Leonardis, Francesco and De Luca, Andrea and Di Biagio, Antonio and Di Perri, Giovanni and Francioso, Simona and Gaeta, Giovanni Battista and Gasbarrini, Antonio and Ghisetti, Valeria and Giorgini, Alessia and Grieco, Antonio and Gubertini, Guido and Gulminetti, Roberto and Lambiase, Lara and Landonio, Simona and Lichtner, Miriam and Maida, Ivana and Marenco, Simona and Marinaro, Letizia and Maserati, Renato and Melis, Michela and Menzaghi, Barbara and Meregalli, Elisa and Micheli, Valeria and Niero, Fosca and Paoloni, Maurizio and Pieri, Alessandro and Rendina, Maria and Romagnoli, Dante and Rossetti, Barbara and Ruggiero, Tina and Sangiovanni, Vincenzo and Starace, Mario and Sticchi, Laura and Tarquini, Pierluigi and Toniutto, Pierluigi and Vullo, Vincenzo and Zazzi, Maurizio and Hcv Virology Italian Resistance Ne and HCV Virology Italian Resistance Network (VIRONET-C)
Scientific Reports, ISSN 2045-2322, 12/2018, Volume 8, Issue 1, pp. 8988 - 11
Natural resistance-associated substitutions (RASs) are reported with highly variable prevalence across different HCV genotypes (GTs). Frequency of natural RASs... 
GLECAPREVIR | TREATMENT-NAIVE | REAL-LIFE | PIBRENTASVIR | CIRRHOSIS | MULTIDISCIPLINARY SCIENCES | SIMEPREVIR PLUS SOFOSBUVIR | RESPONSE RATES | DIRECT-ACTING ANTIVIRALS | 1 INFECTION | OPEN-LABEL | Hepatitis C | Disease resistance | Genotypes
Journal Article
Infection, ISSN 0300-8126, 10/2018, Volume 46, Issue 5, pp. 607 - 615
Journal Article
Journal of Cellular Biochemistry, ISSN 0730-2312, 10/2015, Volume 116, Issue 10, pp. 2188 - 2194
Journal Article
by Di Maio, Velia Chiara and Cento, Valeria and Aragri, Marianna and Paolucci, Stefania and Pollicino, Teresa and Coppola, Nicola and Bruzzone, Bianca and Ghisetti, Valeria and Zazzi, Maurizio and Brunetto, Maurizia and Bertoli, Ada and Barbaliscia, Silvia and Galli, Silvia and Gennari, William and Baldanti, Fausto and Raimondo, Giovanni and Perno, Carlo Federico and Ceccherini-Silberstein, Francesca and Andreone, Pietro and Andreoni, Massimo and Angelico, Mario and Babudieri, Sergio and Barbarini, Giorgio and Boccaccio, Vincenzo and Boglione, Lucio and Bolis, Matteo and Bonora, Stefano and Borghi, Vanni and Brancaccio, Giuseppina and Bruno, Savino and Cacciatore, Pierluigi and Calvaruso, Vincenza and Caporaso, Nicola and Ciaccio, Antonio and Ciancio, Alessia and Colombatto, Piero and Cozzolongo, Raffaele and Craxì, Antonio and D'Ambrosio, Cecilia and D'Ettorre, Gabriella and De Luca, Andrea and Di Biagio, Antonio and Di Perri, Giovanni and Francioso, Simona and Gaeta, Giovanni Battista and Giorgini, Alessia and Grieco, Antonio and Gubertini, Guido and Gulminetti, Roberto and Lambiase, Lara and Lenci, Ilaria and Lichtner, Miriam and Maida, Ivana and Marenco, Simona and Marinaro, Letizia and Maserati, Renato and Masetti, Chiara and Melis, Michela and Meregalli, Elisa and Micheli, Valeria and Morisco, Filomena and Niero, Fosca and Nicolini, Laura Ambra and Palitti, Valeria Pace and Paoloni, Maurizio and Parruti, Giustino and Pasquazzi, Caterina and Pellicelli, Adriano and Polilli, Ennio and Ponti, Maria Laura and Puoti, Massimo and Rendina, Maria and Rizzardini, Giuliano and Rossetti, Barbara and Ruggiero, Tina and Sangiovanni, Vincenzo and Starace, Mario and Sticchi, Laura and Tarquini, Pierluigi and Toniutto, Pierluigi and Vullo, Vincenzo and HCV Virology Italian Resistance Network (VIRONET-C)
Journal of Hepatology, ISSN 0168-8278, 03/2018, Volume 68, Issue 3, pp. 597 - 600
Journal Article
by Caraceni, Paolo and Riggio, Oliviero and Angeli, Paolo and Alessandria, Carlo and Neri, Sergio and Neri, Elga and Foschi, Francesco G and Levantesi, Fabio and Airoldi, Aldo and Boccia, Sergio and Svegliati-Baroni, Gianluca and Fagiuoli, Stefano and Romanelli, Roberto G and Cozzolongo, Raffaele and Di Marco, Vito and Sangiovanni, Vincenzo and Morisco, Filomena and Toniutto, Pierluigi and Tortora, Annalisa and De Marco, Rosanna and Angelico, Mario and Cacciola, Irene and Elia, Chiara and Elia, Gianfranco and Federico, Alessandro and Massironi, Sara and Guarisco, Riccardo and Galioto, Alessandra and Ballardini, Giorgio and Rendina, Maria and Nardelli, Silvia and Piano, Salvatore and Prestianni, Loredana and Cappa, Federica Mirici and Cesarini, Lucia and Simone, Loredana and Pasquale, Chiara and Cavallin, Marta and Andrealli, Alida and Fidone, Federica and Ruggeri, Matteo and Roncadori, Andrea and Baldassarre, Maurizio and Tufoni, Manuel and Zaccherini, Giacomo and Bernardi, Mauro and Domenicali, Marco and Giannone, Ferdinando A and Merli, Manuela and Gioia, Stefania and Fasolato, Silvano and Sticca, Antonietta and Campion, Daniela and Risso, Alessandro and Saracco, Giorgio M and Maiorca, Daniela and Rizzotto, Agostino and Lanzi, Arianna and Visani, Anna and Mastroianni, Antonio and Alberti, Alberto B and Mazzarelli, Chiara and Vangeli, Marcello and Marzioni, Marco and Capretti, Francesca and Kostandini, Alba and Magini, Giulia and Colpani, Maria and Laffi, Giacomo and Gabbani, Tommaso and Marsico, Maria and Zappimbulso, Marianna and Petruzzi, Josè and Calvaruso, Vincenza and Parrella, Giovanni and Caporaso, Nicola and Auriemma, Francesco and Guarino, Maria and Pugliese, Fabio and Gasbarrini, Antonio and Leo, Pietro and De Leonardis, Francesco and Pecchioli, Alessandra and Rossi, Piera and Raimondo, Giovanni and Negri, Elisa and Dallio, Marcello and Loguercio, Carmelina and Conte, Dario and Celli, Natascia and Bringiotti, Roberto and Castellaneta, Nicola M and Salerno, Francesco and ANSWER Study Investigators
The Lancet, ISSN 0140-6736, 06/2018, Volume 391, Issue 10138, pp. 2417 - 2429
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2012, Volume 57, Issue 4, pp. 821 - 829
Background & Aims The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall... 
Gastroenterology and Hepatology | Subset analyses | Time to progression | Hepatocellular carcinoma | Disease control rate | Overall survival | Sorafenib | SURVIVAL | DESIGN | MANAGEMENT | PROGNOSIS | RISK | NATURAL-HISTORY | CIRRHOSIS | STAGING SYSTEMS | CLINICAL-TRIALS | GASTROENTEROLOGY & HEPATOLOGY | EPIDEMIOLOGY | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Liver Neoplasms - therapy | Hand-Foot Syndrome - etiology | Hepatitis C, Chronic - complications | Diarrhea - chemically induced | Liver Neoplasms - etiology | Carcinoma, Hepatocellular - drug therapy | Time Factors | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Female | Liver Neoplasms - pathology | Carcinoma, Hepatocellular - etiology | Alcoholism - complications | Severity of Illness Index | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Niacinamide - adverse effects | Proportional Hazards Models | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Tumor Burden | Disease Progression | Hepatitis B, Chronic - complications | Carcinoma, Hepatocellular - pathology | Aged | Carcinoma, Hepatocellular - therapy | Neoplasm Staging | Antimitotic agents | Medical colleges | Liver cancer | Care and treatment | Analysis | Clinical trials | Product development | Hepatoma | Antineoplastic agents
Journal Article